Lv21
170 积分 2023-05-18 加入
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
6天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
6天前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
10天前
已完结
Cancer cachexia contender enters first pivotal trial
16天前
已完结
PK/PD Evaluation of Antibody–Drug Conjugates with Enhanced Immune Effector Functions
16天前
已完结
Current status and future perspectives of FGF21 analogues in clinical trials
1个月前
已完结
Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
1个月前
已完结
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
1个月前
已完结
A new target for cancer cachexia
2个月前
已完结
Targeting GDF-15 in cancer cachexia and immunity
2个月前
已完结
The Underlying Mechanism of 3-Hydroxyphthalic Anhydride-Modified Bovine Beta-Lactoglobulin to Block Human Papillomavirus Entry Into the Host Cell
皖公网安备34019202002308
